EMA and European Chemicals Agency Strengthen Collaboration - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

EMA and European Chemicals Agency Strengthen Collaboration

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 6

The European Medicines Agency (EMA) and the European Chemicals Agency (ECHA) have entered into an agreement to strengthen the scientific dialogue between the two organizations through sharing expertise and scientific data between their scientific committees, working groups, and panels on matters of common interest.

The working agreement, signed by EMA Executive Director Guido Rasi and ECHA Executive Director Geert Dancet, outlines activities to ensure the best use of available resources and ensure coherence in scientific opinions. The organizations agree to exchange information regarding evaluation and authorization/restriction of chemicals, as relevant for the activities of EMA; share information concerning risk management through classification, labeling, and packaging of substances; cooperate on toxicological assessments by predictive methods and new methodologies; cooperate on biocides; exchange information on environmental risk assessment for both human and veterinary medicinal products and ecotoxicology; and participate in meetings and joint projects.

Source: European Medicines Agency

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here